晚期痴呆养老院居民临终前使用可能无益药物的情况
该研究基于加拿大安大略省养老院居民评估数据,纳入9298名晚期痴呆死亡居民,分析临终前120天及最后1周可能无益药物(MQBs)的使用情况。结果显示86.3%在最后120天、45.0%在最后1周仍使用MQBs,最常见为抗痴呆药和降脂药。严重认知障碍和健康不稳定症状较少与最后1周MQB使用相关。
要点
- 晚期痴呆养老院居民中,45.0%在生命最后1周仍使用可能无益药物。
- 最常见MQBs为抗痴呆药(63.6%)和降脂药(47.8%)。
- 严重认知障碍和健康不稳定症状较少与临终前MQB使用相关。
核心结论
- 许多晚期痴呆养老院居民在生命最后1周仍被处方可能无益药物,医师应主动重新评估临终阶段所有药物的作用。
研究设计与样本
- 基于人群的横断面研究,使用居民评估工具最小数据集2.0链接健康行政数据,覆盖加拿大安大略省。
- 纳入9298名晚期痴呆养老院居民,均在2010年6月1日至2013年3月31日期间死亡、死亡时年龄≥66岁且最后1年至少接受过1种MQB。
主要发现
- 在最后1年至少接受1种MQB的晚期痴呆养老院居民中,8027人(86.3%)在最后120天接受MQBs,4180人(45.0%)在最后1周接受MQBs。
- 最常处方的MQB为抗痴呆药(63.6%)和降脂药(47.8%)。
- 严重认知障碍与最后1周MQB使用相关(aOR=1.19,95%CI=1.07-1.33,P=.002)。
- 健康不稳定症状较少与最后1周MQB使用相关(aOR=1.58,95%CI=1.44-1.74,P<.001)。
- 就诊神经科或精神科医生与最后1周MQB使用可能性较低相关。
关键数值与推荐
- MQBs包括8类药物(如降脂药、抗痴呆药),评估时间窗为生命最后120天和最后1周。
临床怎么用
- 对晚期痴呆养老院居民,临终前应主动重新评估所有药物,尤其是抗痴呆药和降脂药等可能无益药物。
- 关注严重认知障碍和健康状态相对稳定者,其临终前MQB使用风险较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the prevalence of and resident characteristics associated with the prescription of medications of questionable benefit (MQBs) near the end of life in older adults with advanced dementia in nursing homes. DESIGN: Population-based, cross-sectional study using Resident Assessment Instrument Minimum Data Set 2.0 linked to health administrative data. SETTING: Ontario, Canada. PARTICIPANTS: All 9,298 nursing home residents with advanced dementia who died between June 1, 2010, and March 31, 2013; were aged 66 and older at time of death; and received at least one MQB in their last year of life. MEASUREMENTS: Prevalence of eight classes of MQBs (e.g., lipid-lowering agents, antidementia drugs) used in the last 120 days and last week of life. RESULTS: Of older nursing home residents with advanced dementia who received at least one MQB in the last year of life, 8,027 (86.3%) received them in the last 120 days and 4,180 (45.0%) in the last week of life. The most commonly prescribed MQB were antidementia (63.6%) and lipid-lowering agents (47.8%). Severe cognitive impairment (adjusted odds ratio (aOR) = 1.19, 95% confidence interval (CI) = 1.07-1.33, P = .002) and fewer signs and symptoms of health instability (aOR = 1.58, 95% CI = 1.44-1.74, P < .001) were associated with MQB use into the last week of life. Seeing a neurologist or psychiatrist was associated with less likelihood of MQB use in the last week of life. CONCLUSION: Many nursing home residents with advanced dementia are dispensed MQBs in the last week of life. Given that MQBs may cause more harm than benefit in this vulnerable population, it is important for physicians to actively reassess the role of all medications toward the end of life.
引用
- Matlow JN, Bronskill SE, Gruneir A, et al. Use of Medications of Questionable Benefit at the End of Life in Nursing Home Residents with Advanced Dementia. J Am Geriatr Soc. 2017. PMID: 28369696. doi:10.1111/jgs.14844
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。